MOLOGNI LUCA
- U08, Piano: 4, Stanza: LABORATORIO 4.10
- U08, Piano: 4, Stanza: 4043
Pubblicazioni
Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Dettaglio
Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio
Introvigne, M., Destro, L., Mologni, L., Crippa, V., Zardi, P., Fini, F., et al. (2025). α-Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML. CHEMMEDCHEM, 20(1) [10.1002/cmdc.202400622]. Dettaglio
Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Dettaglio
Pattabiraman, N., Lobello, C., Rushmore, D., Mologni, L., Wasik, M., Basappa, J. (2025). A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma. CANCERS, 17(20) [10.3390/cancers17203389]. Dettaglio